Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
considerations for the company's lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer's 36th Annual Healthcare and Life Sciences Conference. Program overview and development history Chief Executive Officer Dr. Javier Szwarcberg discussed Spruce's enzyme replacement therapy program, referred to in the discussion as “TA-ERT,” which is designed for central nervous system (CNS) delivery. Unlike most enzyme replacement therapies that are administered intravenously and have limited penetration into the brain, Szwarcberg said this therapy is administered directly into the cerebrospinal fluid (CSF) via intracerebroventricular (ICV) delivery using an Ommaya reservoir. He said this approach is intended to address the profound CNS involvement in neuronopathic forms of mucopolysaccharidoses, including MPS IIIB. ? AI Is Separating Software Winners From Losers, 2 Experts Explain Szwarcberg said the therapy was originally developed at BioMarin as a fusi
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- BioMarin Pharmaceutical (BMRN) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- BioMarin Pharmaceutical (BMRN) was given a new $105.00 price target by Loop Capital.MarketBeat
- A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here's Why [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 2/23/26 - Beat
BMRN
Sec Filings
- 2/26/26 - Form 4
- 2/26/26 - Form 4
- 2/26/26 - Form 4
- BMRN's page on the SEC website